Two different definitions of trifecta outcomes after partial nephrectomy are available in Literature, one requiring a volumetric assessment of percentage of parenchyma spared [1], the other requiring a conventional on-clamp approach to be used [2]. Recently, the US FDA and the National Kidney Foundation recommended to consider a 30% decrease of eGFR as a clinically relevant acute kidney injury with potential implication on long term development of chronic kidney disease [3]. The aim of this study is to integrate this data into trifecta system for an easy and wide clinical use in patients treated with RAPN for cT1 renal tumor and to assess factors predicting its achievement.

A novel trifecta to simplify the assessment of perioperative outcomes after robot assisted partial nephrectomy for cT1 renal masses: Results of a multicenter series / Anceschi, U.; Bertolo, R.; Brassetti, A.; Tuderti, G.; Guaglianone, S.; Garisto, J.; Kaouk, J.; Mottrie, A.; Dell’oglio, P.; Veccia, A.; Antonelli, A.; Capitanio, U.; Montorsi, F.; Larcher, A.; Minervini, A.; Porpiglia, F.; Aron, M.; Ithaar, D.; Autorino, R.; Swavely, N.; Eun, D.; Ferriero, M.; Gallucci, M.. - In: EUROPEAN UROLOGY. SUPPLEMENTS. - ISSN 1569-9056. - ELETTRONICO. - 18:(2019), pp. 0-0. [10.1016/S1569-9056(19)30325-2]

A novel trifecta to simplify the assessment of perioperative outcomes after robot assisted partial nephrectomy for cT1 renal masses: Results of a multicenter series

Minervini, A.;
2019

Abstract

Two different definitions of trifecta outcomes after partial nephrectomy are available in Literature, one requiring a volumetric assessment of percentage of parenchyma spared [1], the other requiring a conventional on-clamp approach to be used [2]. Recently, the US FDA and the National Kidney Foundation recommended to consider a 30% decrease of eGFR as a clinically relevant acute kidney injury with potential implication on long term development of chronic kidney disease [3]. The aim of this study is to integrate this data into trifecta system for an easy and wide clinical use in patients treated with RAPN for cT1 renal tumor and to assess factors predicting its achievement.
2019
Anceschi, U.; Bertolo, R.; Brassetti, A.; Tuderti, G.; Guaglianone, S.; Garisto, J.; Kaouk, J.; Mottrie, A.; Dell’oglio, P.; Veccia, A.; Antonelli, A.; Capitanio, U.; Montorsi, F.; Larcher, A.; Minervini, A.; Porpiglia, F.; Aron, M.; Ithaar, D.; Autorino, R.; Swavely, N.; Eun, D.; Ferriero, M.; Gallucci, M.
File in questo prodotto:
File Dimensione Formato  
anceschi2019.pdf

Accesso chiuso

Descrizione: Articolo principale
Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 161.65 kB
Formato Adobe PDF
161.65 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1157118
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact